HRP20182114T1 - Spojevi 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-ona i njihova uporaba kao negativnih alosternih modulatora receptora mglu2 - Google Patents

Spojevi 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-ona i njihova uporaba kao negativnih alosternih modulatora receptora mglu2

Info

Publication number
HRP20182114T1
HRP20182114T1 HRP20182114TT HRP20182114T HRP20182114T1 HR P20182114 T1 HRP20182114 T1 HR P20182114T1 HR P20182114T T HRP20182114T T HR P20182114TT HR P20182114 T HRP20182114 T HR P20182114T HR P20182114 T1 HRP20182114 T1 HR P20182114T1
Authority
HR
Croatia
Prior art keywords
dihydropyrazolo
pyrazin
compounds
allosteric modulators
negative allosteric
Prior art date
Application number
HRP20182114TT
Other languages
English (en)
Inventor
Sergio-Alvar Alonso-De Diego
Michiel Luc Maria Van Gool
María Luz MARTÍN-MARTÍN
Susana Conde-Ceide
José Ignacio ANDRÉS-GIL
Óscar DELGADO-GONZÁLEZ
Gary John Tresadern
Andrés Avelino TRABANCO-SUÁREZ
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HRP20182114T1 publication Critical patent/HRP20182114T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HRP20182114TT 2014-08-01 2018-12-13 Spojevi 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-ona i njihova uporaba kao negativnih alosternih modulatora receptora mglu2 HRP20182114T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14179600 2014-08-01
EP14196083 2014-12-03
EP15744915.8A EP3174883B1 (en) 2014-08-01 2015-07-30 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglu2 receptors
PCT/EP2015/067572 WO2016016395A1 (en) 2014-08-01 2015-07-30 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors

Publications (1)

Publication Number Publication Date
HRP20182114T1 true HRP20182114T1 (hr) 2019-02-08

Family

ID=53765202

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20182114TT HRP20182114T1 (hr) 2014-08-01 2018-12-13 Spojevi 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-ona i njihova uporaba kao negativnih alosternih modulatora receptora mglu2

Country Status (30)

Country Link
US (2) US10005785B2 (hr)
EP (1) EP3174883B1 (hr)
JP (1) JP6609306B2 (hr)
KR (1) KR102531680B1 (hr)
CN (1) CN107018662B (hr)
AU (1) AU2015295313B2 (hr)
BR (1) BR112017001861A2 (hr)
CA (1) CA2954094C (hr)
CL (1) CL2017000249A1 (hr)
CY (1) CY1121123T1 (hr)
DK (1) DK3174883T3 (hr)
EA (1) EA033052B1 (hr)
ES (1) ES2705425T3 (hr)
HR (1) HRP20182114T1 (hr)
HU (1) HUE041777T2 (hr)
IL (1) IL250303A0 (hr)
JO (1) JOP20150177B1 (hr)
LT (1) LT3174883T (hr)
ME (1) ME03341B (hr)
MX (1) MX370182B (hr)
NZ (1) NZ728025A (hr)
PH (1) PH12017500170B1 (hr)
PL (1) PL3174883T3 (hr)
PT (1) PT3174883T (hr)
RS (1) RS58215B1 (hr)
SG (1) SG11201700637WA (hr)
SI (1) SI3174883T1 (hr)
TW (1) TWI688566B (hr)
WO (1) WO2016016395A1 (hr)
ZA (1) ZA201700758B (hr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20150179B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
JOP20150177B1 (ar) * 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
CA2967542C (en) 2014-12-03 2022-11-29 Janssen Pharmaceutica Nv Radiolabelled mglur2 pet ligands
EP3227295B1 (en) * 2014-12-03 2019-02-20 Janssen Pharmaceutica NV 6,7-dihydropyrazolo[1,5- ]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglu2 receptors
SI3389727T1 (sl) 2015-12-18 2020-10-30 Janssen Pharmaceutica Nv Radioaktivno označeni ligandi PET MGLUR2/3
ES2820823T3 (es) * 2015-12-18 2021-04-22 Janssen Pharmaceutica Nv Ligandos PET mGluR2/3 radiomarcados
JP2020011902A (ja) * 2016-10-26 2020-01-23 大日本住友製薬株式会社 縮環ピロール誘導体およびその医薬用途
AU2018373464B2 (en) 2017-11-24 2022-12-08 Sumitomo Pharma Co., Ltd. 6,7-dihydropyrazolo[1,5-a] pyrazinone derivative and medical use thereof
WO2024008909A1 (en) 2022-07-08 2024-01-11 Janssen Pharmaceutica Nv Inhibitors of coronavirus

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0756200B1 (en) 1995-07-26 1999-11-10 Konica Corporation Silver halide color photographic light-sensitive material
DE19653647A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
US6482821B2 (en) 1996-12-20 2002-11-19 Hoechst Aktiengellschaft Vitronectin receptor antagonists, their preparation and their use
US6754375B1 (en) 1999-07-16 2004-06-22 Packard Bioscience Company Method and system for interactively developing at least one grid pattern and computer-readable storage medium having a program for executing the method
US6831074B2 (en) 2001-03-16 2004-12-14 Pfizer Inc Pharmaceutically active compounds
US20030114448A1 (en) 2001-05-31 2003-06-19 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
WO2005061507A1 (en) 2003-12-16 2005-07-07 Pfizer Products Inc. Bicyclic pyrazol-4-one cannabinoid receptor ligands and uses thereof
WO2006030847A1 (ja) 2004-09-17 2006-03-23 Dainippon Sumitomo Pharma Co., Ltd. 新規二環性ピラゾール誘導体
DE102004054665A1 (de) * 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte bi- und tricyclische Pyrazol-Derivate Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
WO2007084314A2 (en) 2006-01-12 2007-07-26 Incyte Corporation MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
JP5523829B2 (ja) 2006-06-29 2014-06-18 アステックス、セラピューティックス、リミテッド 複合薬剤
WO2008141249A1 (en) 2007-05-10 2008-11-20 Acadia Pharmaceuticals Inc. Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors
EP2085390A1 (en) 2008-01-31 2009-08-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors
US9446995B2 (en) 2012-05-21 2016-09-20 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
PT2268612E (pt) 2008-03-24 2014-11-13 Novartis Ag Inibidores de metaloprotease de matriz à base de arilsulfonamidas
WO2009130232A1 (en) 2008-04-24 2009-10-29 Glaxo Group Limited Pyrazolo [1, 5 -a] pyrazine derivatives as antagonists of v1b receptors
EP2327704A4 (en) 2008-08-29 2012-05-09 Shionogi & Co RING-CONDENSED AZOL DERIVATIVE WITH PI3K-INHIBITING EFFECT
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
EP2627648A1 (en) 2010-09-16 2013-08-21 Novartis AG 17aHYDROXYLASE/C17,20-LYASE INHIBITORS
WO2012062752A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. RADIOLABELLED mGLuR2 PET LIGANDS
AU2011343477A1 (en) * 2010-12-17 2013-07-04 Vanderbilt University Bicyclic triazole and pyrazole lactams as allosteric modulators of mGluR5 receptors
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
KR20140063605A (ko) 2011-07-19 2014-05-27 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
WO2013012915A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
MY167423A (en) 2011-11-03 2018-08-27 Merck Sharp & Dohme Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use
JP5783264B2 (ja) 2011-11-25 2015-09-24 日本電気株式会社 セル識別子割当方法、基地局、保守サーバ、移動通信システム
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20130281397A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
EP2666775A1 (en) 2012-05-21 2013-11-27 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
US20130345204A1 (en) * 2012-06-20 2013-12-26 Vanderbilt University Substituted bicyclic cycloalkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors
US20130345205A1 (en) * 2012-06-20 2013-12-26 Vanderbilt University Substituted bicyclic aralkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors
CN104736156A (zh) * 2012-06-20 2015-06-24 范德比尔特大学 作为mglur5受体变构调节剂的取代的双环烷氧基吡唑类似物
EP2925292A1 (en) 2012-10-23 2015-10-07 F. Hoffmann-La Roche AG Mglu2/3 antagonists for the treatment of autistic disorders
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
CA2916653C (en) 2013-06-27 2017-07-18 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
DK3030563T3 (da) 2013-06-27 2017-11-20 Janssen Sciences Ireland Uc Pyrrolo-[3,2-d]-pyrimidin-derivater til behandling af virale infektioner og andre sygdomme
CN107001373B (zh) 2014-08-01 2020-01-07 詹森药业有限公司 6,7-二氢吡唑并[1,5-a]吡嗪-4(5H)-酮化合物及其作为MGLUR2受体的负向别构调节剂的用途
JO3601B1 (ar) 2014-08-01 2020-07-05 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
JOP20150179B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
JOP20150177B1 (ar) * 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
CN107018661B (zh) 2014-08-01 2020-01-03 詹森药业有限公司 6,7-二氢吡唑并[1,5-a]吡嗪-4(5H)-酮化合物及其作为MGLUR2受体的负向别构调节剂的用途
CA2967542C (en) 2014-12-03 2022-11-29 Janssen Pharmaceutica Nv Radiolabelled mglur2 pet ligands
EP3227295B1 (en) 2014-12-03 2019-02-20 Janssen Pharmaceutica NV 6,7-dihydropyrazolo[1,5- ]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglu2 receptors
SI3389727T1 (sl) 2015-12-18 2020-10-30 Janssen Pharmaceutica Nv Radioaktivno označeni ligandi PET MGLUR2/3
ES2820823T3 (es) 2015-12-18 2021-04-22 Janssen Pharmaceutica Nv Ligandos PET mGluR2/3 radiomarcados

Also Published As

Publication number Publication date
EA201692544A1 (ru) 2017-08-31
EP3174883A1 (en) 2017-06-07
AU2015295313A1 (en) 2017-01-05
AU2015295313B2 (en) 2019-05-02
ES2705425T3 (es) 2019-03-25
CA2954094A1 (en) 2016-02-04
CA2954094C (en) 2023-02-14
IL250303A0 (en) 2017-03-30
US10519162B2 (en) 2019-12-31
CN107018662B (zh) 2020-01-07
KR20170033373A (ko) 2017-03-24
US20180258096A1 (en) 2018-09-13
EA033052B1 (ru) 2019-08-30
RS58215B1 (sr) 2019-03-29
SG11201700637WA (en) 2017-02-27
MX2017001454A (es) 2017-05-09
TWI688566B (zh) 2020-03-21
LT3174883T (lt) 2019-01-10
ZA201700758B (en) 2020-01-29
ME03341B (me) 2019-10-20
CY1121123T1 (el) 2019-12-11
TW201625630A (zh) 2016-07-16
NZ728025A (en) 2022-04-29
PH12017500170A1 (en) 2017-07-10
PH12017500170B1 (en) 2017-07-10
SI3174883T1 (sl) 2019-01-31
BR112017001861A2 (pt) 2017-11-21
US10005785B2 (en) 2018-06-26
CN107018662A (zh) 2017-08-04
JP2017526659A (ja) 2017-09-14
CL2017000249A1 (es) 2017-08-18
EP3174883B1 (en) 2018-10-24
JP6609306B2 (ja) 2019-11-20
US20170217971A1 (en) 2017-08-03
JOP20150177B1 (ar) 2021-08-17
DK3174883T3 (en) 2019-02-04
KR102531680B1 (ko) 2023-05-10
HUE041777T2 (hu) 2019-05-28
MX370182B (es) 2019-12-04
PL3174883T3 (pl) 2019-04-30
WO2016016395A1 (en) 2016-02-04
PT3174883T (pt) 2019-01-21

Similar Documents

Publication Publication Date Title
HRP20181997T1 (hr) Spojevi 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-ona i njihova uporaba kao negativnih alosternih modulatora receptora mglu2
HRP20182114T1 (hr) Spojevi 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-ona i njihova uporaba kao negativnih alosternih modulatora receptora mglu2
IL242868B (en) 7,6-dihydropyrazolo[5,1-a]pyrazine-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
IL290905B1 (en) Crystal form of (s)–n-(5–)–2–(r))5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-a]pyrimidine-3-yl)-3 -Hydroxypyrrolidine-1-carboxamide hydrogen sulfate
IL243676B (en) 4,2,1-triazolo[3,4-a]pyridine compounds and their use as positive allosteric modulators of mglur2 receptors
TH1701000552A (th) สารประกอบ 6,7-ไดไฮโดรไพราโซโล[1,5-a]ไพราซีน-4(5H)-โอน และการใช้ของพวกมันเป็นเนกาทีฟ อัลโลสเตอริก มอดูเลเตอร์ของ MGLUR2 รีเซปเตอร์